NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Market Cap: US$128.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NGM Biopharmaceuticals Management

Management criteria checks 2/4

NGM Biopharmaceuticals' CEO is David Woodhouse, appointed in Sep 2018, has a tenure of 5.58 years. total yearly compensation is $5.93M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $179.29K. The average tenure of the management team and the board of directors is 1.3 years and 5.6 years respectively.

Key information

David Woodhouse

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage10.28%
CEO tenure5.6yrs
CEO ownership0.1%
Management average tenure1.3yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Analysis Article • Dec 19

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • Oct 05

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Aug 09

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Today is shaping up negative for NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders, with the analysts delivering...
Analysis Article • Jun 27

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Apr 17

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

NGM Biopharmaceuticals, Inc.'s ( NASDAQ:NGM ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong...
Analysis Article • Dec 20

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 17

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

NGM Biopharmaceuticals (NASDAQ:NGM) on Monday said its phase 2 trial of its monoclonal antibody NGM621 for the treatment of eye disease geographic atrophy failed to meet its main goal. Shares of the small-cap biotech plunged 72.2% to $3.21 in premarket trading. The mid-stage trial, called CATALINA, was evaluating NGM621 for patients with geographic atrophy (GA), which is the progressive degeneration of the macula in the eye and is an advanced form of age-related macular degeneration. NGM said the trial did not meet the primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham. However, the company said the treatment showed favorable safety and tolerability. The company plans to present further analyses in early Nov. at a conference.
Seeking Alpha • Jun 30

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Siobhan Nolan Mangini, CFO of NGM Biopharmaceuticals (NASDAQ:NGM) has been appointed to the additional role of President. David J. Woodhouse, Ph.D. will continue to serve as NGM Bio’s Chief Executive Officer. William J. Rieflin, who has served as Executive Chairman of company’s Board since September 2018, will transition to Chairman of the Board effective July 1, 2022.
Seeking Alpha • Jun 21

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Results from the phase 2 CATALINA study using NGM621 for the treatment of patients with Geographic Atrophy are expected in the 2nd half of 2022. Results from a phase 1/2 study using NGM707 for the treatment of patients with advanced cancer are expected in the 2nd half of 2022. Results from the phase 2b ALPINE4 study using aldafermin for the treatment of patients with compensated NASH cirrhosis are expected 1st half of 2023. NGM Biopharmaceuticals had $329.8 million in cash as of March 31, 2022. It believes it has enough cash to fund its operations for at least the next 12 months.
Analysis Article • Jun 15

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 09

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

Celebrations may be in order for NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders, with the analysts delivering...
Seeking Alpha • Apr 26

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

After last year's NASH flop, NGM was written off as a lost cause. The company has been able to turn itself around. Today it is an oncology-focused company with multiple interesting assets.
Analysis Article • Feb 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Nov 08

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jul 09

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Mar 06

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Last week, you might have seen that NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) released its full-year result to the...

CEO Compensation Analysis

How has David Woodhouse's remuneration changed compared to NGM Biopharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$142m

Sep 30 2023n/an/a

-US$151m

Jun 30 2023n/an/a

-US$170m

Mar 31 2023n/an/a

-US$178m

Dec 31 2022US$6mUS$610k

-US$163m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$135m

Mar 31 2022n/an/a

-US$125m

Dec 31 2021US$10mUS$580k

-US$120m

Sep 30 2021n/an/a

-US$121m

Jun 30 2021n/an/a

-US$122m

Mar 31 2021n/an/a

-US$111m

Dec 31 2020US$5mUS$525k

-US$102m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$490k

-US$43m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$4mUS$413k

-US$493k

Compensation vs Market: David's total compensation ($USD5.93M) is above average for companies of similar size in the US market ($USD662.79K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Woodhouse (52 yo)

5.6yrs
Tenure
US$5,933,500
Compensation

Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...

Leadership Team

NamePositionTenureCompensationOwnership
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Valerie Pierce
Senior VP4.5yrsUS$2.10m0.022%
$ 28.7k
Hsiao Lieu
Chief Medical Officer & Executive VP5.1yrsUS$2.73m0.017%
$ 22.3k
Jean Frederic Viret
Chief Financial Officer1.3yrsno datano data
Irene Perlich
VP, Corporate Controller & Principal Accounting Officerless than a yearno data0.011%
$ 13.8k
Daniel Kaplan
Chief Scientific Officer1.3yrsno datano data
Mahi Saraf
Director of People & Cultureless than a yearno datano data
Diana Bockus
Head of Business Development1.8yrsno datano data
Arthur Hsu
Senior Director & Head of Biology1.3yrsno datano data
Kara Calhoun
Senior Vice President of CMC & Process Developmentless than a yearno datano data
1.3yrs
Average Tenure
56.5yo
Average Age

Experienced Management: NGM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Grant Heidrich
Special Advisorno datano datano data
Arthur Levinson
Special Advisorno datano datano data
David Goeddel
Lead Independent Director5.6yrsUS$270.23k19.87%
$ 25.5m
Michael Brown
Chairman of the Scientific Advisory Boardno datano datano data
Joseph Goldstein
Member of the Scientific Advisory Boardno datano datano data
Roger Perlmutter
Independent Director2.8yrsUS$250.00k0%
$ 0
Shelly Guyer
Independent Director4.3yrsUS$273.09k0%
$ 0
Robert Schreiber
Member of Scientific Advisory Boardno datano datano data
Suzanne Hooper
Independent Director5.7yrsUS$265.00k0.0084%
$ 10.8k
Michael Fischbach
Member of Scientific Advisory Boardno datano datano data
5.6yrs
Average Tenure
67yo
Average Age

Experienced Board: NGM's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/05 04:55
End of Day Share Price 2024/04/05 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NGM Biopharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Paul ChoiGoldman Sachs